Literature DB >> 16689180

Safety of specific immunotherapy using a four-hour ultra-rush induction scheme in bee and wasp allergy.

A Roll1, G Hofbauer, B K Ballmer-Weber, P Schmid-Grendelmeier.   

Abstract

BACKGROUND: Ultra-rush induction of immunotherapy with Hymenoptera venom is a reliable and efficacious alternative to the rush induction protocol, though not widely used in European countries yet. Its safety, however, has been intensively discussed over the last few years. The aim of this retrospective case study was to examine the rate of allergic side-effects during our four-hour ultra-rush hymenoptera venom induction regimen. We evaluated risk factors for observed side-effects such as age, gender, severity of previous insect sting reactions according to the H.L. Mueller classification, concentration of venom inducing positive skin tests, level of specific IgE, serum tryptase concentration, and hymenoptera venom used for treatment.
METHODS: 67 outpatients with Hymenoptera venom allergy received 80 courses of ultra-rush immunotherapy. Diagnosis and selection of patients for venom immunotherapy were carried out according to the European Academy of Allergology and Clinical Immunology. We applied a four-hour regimen, and local or systemic reactions were documented.
RESULTS: In 78 courses (97.5%) the maintenance dose of 111.1 microg was reached within 4 hours and it was tolerated in 82.5% without any hypersensitivity reaction. Allergic side-effects were observed in only 17.5% (n=14): four severe local reactions (5%), eight grade I (10%) and two grade II (2.5%) systemic reactions. There was no significant difference in the number of systemic reactions comparing patients receiving wasp or honeybee venom extract. The number of systemic reactions was neither higher in patients with a severe prior insect sting reaction (grade III or IV) nor dependent on age, gender, skin test reaction, level of specific IgE or tryptase. Epinephrine as rescue medication was never needed. Interestingly, patients with a severe prior wasp sting reaction showed a significantly lower incidence of allergic side-effects during ultra-rush immunotheraphy with wasp venom extract as compared to grade III or IV honeybee venom allergic patients.
CONCLUSION: Our ultra-rush immunotherapy induction regimen shows a low incidence of systemic reactions. It proved to be safe and convenient for the patient, as it could be applied in a four-hour outpatient regimen.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16689180

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  13 in total

Review 1.  Chinese Guideline on allergen immunotherapy for allergic rhinitis.

Authors:  Yixiao Bao; Jianjun Chen; Lei Cheng; Yinshi Guo; Suling Hong; Weijia Kong; He Lai; Houyong Li; Huabin Li; Jing Li; Tianying Li; Xiaoping Lin; Shixi Liu; Zheng Liu; Hongfei Lou; Juan Meng; Qianhui Qiu; Kunling Shen; Wei Tang; Zezhang Tao; Chengshuo Wang; Xiangdong Wang; Qingyu Wei; Li Xiang; Hua Xie; Yu Xu; Gehua Zhang; Yuan Zhang; Yiwu Zheng; Yuxiang Zhi; Dehua Chen; Haiyu Hong; Quansheng Li; Lin Liu; Yifan Meng; Nan Wang; Yihui Wang; Yue Zhou; Luo Zhang
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

Review 2.  Accelerated immunotherapy schedules.

Authors:  Christopher W Calabria
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

3.  Induction of specific immunotherapy with hymenoptera venoms using ultrarush regimen in children: safety and tolerance.

Authors:  Alice Köhli-Wiesner; Lisbeth Stahlberger; Christian Bieli; Tamar Stricker; Roger Lauener
Journal:  J Allergy (Cairo)       Date:  2011-07-19

4.  Mechanisms of allergen-specific immunotherapy.

Authors:  Hiroyuki Fujita; Michael B Soyka; Mübeccel Akdis; Cezmi A Akdis
Journal:  Clin Transl Allergy       Date:  2012-01-05       Impact factor: 5.871

5.  Hymenoptera Venom Immunotherapy: Tolerance and Efficacy of an Ultrarush Protocol versus a Rush and a Slow Conventional Protocol.

Authors:  Vincenzo Patella; Giovanni Florio; Ada Giuliano; Carmine Oricchio; Giuseppe Spadaro; Gianni Marone; Arturo Genovese
Journal:  J Allergy (Cairo)       Date:  2012-05-24

Review 6.  Risk associated with bee venom therapy: a systematic review and meta-analysis.

Authors:  Jeong Hwan Park; Bo Kyung Yim; Jun-Hwan Lee; Sanghun Lee; Tae-Hun Kim
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

7.  Safety and efficacy of tree pollen specific immunotherapy on the ultrarush administration schedule method using purethal trees.

Authors:  Andrzej Bozek; Krzysztof Kolodziejczyk; Jerzy Jarzab
Journal:  Biomed Res Int       Date:  2014-03-24       Impact factor: 3.411

8.  Venom allergy treatment practices in Poland in comparison to guidelines: next edition of the national audit.

Authors:  Ewa Cichocka-Jarosz; Marcin Stobiecki; Marita Nittner-Marszalska; Urszula Jedynak-Wąsowicz; Piotr Brzyski
Journal:  Postepy Dermatol Alergol       Date:  2019-06-19       Impact factor: 1.837

9.  Management of insect sting hypersensitivity: an update.

Authors:  Robert D Pesek; Richard F Lockey
Journal:  Allergy Asthma Immunol Res       Date:  2013-02-25       Impact factor: 5.764

Review 10.  [Venom immunotherapy. Side effects and efficacy of treatment].

Authors:  F Ruëff; B Przybilla
Journal:  Hautarzt       Date:  2008-03       Impact factor: 1.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.